Organon & Co’s filing revealed that its Director COX CARRIE SMITH acquired Company’s shares for reported $0.1 million on May 14 ’25. In the deal valued at $8.07 per share,12,469 shares were bought. As a result of this transaction, COX CARRIE SMITH now holds 12,469 shares worth roughly $0.12 million.
Then, Falcione Aaron bought 5,500 shares, generating $48,235 in total proceeds. Upon buying the shares at $8.77, the Chief Human Resources Officer now owns 62,974 shares.
Before that, Weaver Kirke bought 8,045 shares. Organon & Co shares valued at $74,054 were divested by the Gen. Counsel & Corp. Secy. at a price of $9.21 per share. As a result of the transaction, Weaver Kirke now holds 52,489 shares, worth roughly $0.51 million.
Evercore ISI downgraded its Organon & Co [OGN] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in early September from “a Neutral” to “an Underweight”. Goldman also remained covering OGN and has decreased its forecast on November 03, 2023 with a “Neutral” recommendation from previously “Buy” rating. Barclays started covering the stock on September 21, 2023. It rated OGN as “an Overweight”.
Price Performance Review of OGN
On Monday, Organon & Co [NYSE:OGN] saw its stock jump 0.51%% to $9.8. Over the last five days, the stock has lost -2.39%. Organon & Co shares have fallen nearly -51.84% since the year began. Nevertheless, the stocks have fallen -34.32% over the past one year. While a 52-week high of $23.10 was reached on 02/13/25, a 52-week low of $8.01 was recorded on 05/14/25.
Levels Of Support And Resistance For OGN Stock
The 24-hour chart illustrates a support level at 9.56, which if violated will result in even more drops to 9.31. On the upside, there is a resistance level at 9.94. A further resistance level may holdings at 10.08.
The most recent change occurred on March 16, 2023 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $33 price target.
